Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

Each night, our brains execute a "wash and rinse" routine that clears away harmful protein waste linked to neurodegenerative ...

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, ...

Bristol Myers Squibb (NYSE:BMY) believes Alzheimer’s is the largest market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in revenue.

A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Despite initial slow sales, the firm's CEO cited areas for Leqembi's growth and ambitions for an antisense oligonucleotide ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...